At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 368 enrolled
Drug / intervention
BTX 1503 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating BTX 1503 and Vehicle for Acne Vulgaris. Completed, enrolled 368 participants across 36 sites in 2 countries.
Detailed Summary
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesAustralia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJun 2018
Primary CompletionAug 2019
Study CompletionSep 2019
TodayJul 2026
First PostedJun 29, 2018
Enrollment StartJun 26, 2018
Primary CompletionAug 16, 2019
Study CompletionSep 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.0 years ago
Interventions
BTX 1503drug
BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
Vehicledrug
Placebo